Literature DB >> 826944

Effect of some cannabinoids on naloxone-precipitated abstinence in morphine-dependent mice.

H N Bhargava.   

Abstract

Mice were rendered morphine-dependent by the subcutaneous implantation of a pellet containing 75 mg of morphine base; 72 h after the implantation, the animals were injected intraperitoneally either with vehicle or with various doses of delta9-tetrahydrocannabinol, delta8-tetrahydrocannabinol, cannabidiol, cannabinol, or 11-hydroxy-delta8-tetrahydrocannabinol. Thirty minutes after injection of the cannabinoids, the antagonist, naloxone HC1, was administered to induce the stereotyped withdrawal jumping syndrome. The dose of naloxone needed to induce withdrawal jumping in 50% of the animals (ED50) was determined for each dose of the cannabinoids. All of the cannabinoids inhibited the naloxone-precipitated morphine abstinence as evidenced by an increase in the naloxone ED50. Two additional signs of morphine abstinence, defecation and rearing behavior, were also suppressed by the cannabinoids. The relative effectiveness of the cannabinoids in inhibiting morphine abstinence appeared to be in the following order: delta9-tetrahydrocannabinol greater than delta8-tetrahydrocannabinol greater than 11-hydroxy-delta8-tetrahydrocannabinol greater than cannabidiol greater than cannabinol. These data suggest that cannabinoids may be useful in facilitating narcotic detoxification.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 826944     DOI: 10.1007/BF00426828

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  24 in total

1.  Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol.

Authors:  B Hine; E Friedman; M Torrelio; S Gershon
Journal:  Science       Date:  1975-02-07       Impact factor: 47.728

Review 2.  Structure-activity relationships in man of cannabis constituents, and homologs and metabolites of delta9-tetrahydrocannabinol.

Authors:  L E Hollister
Journal:  Pharmacology       Date:  1974       Impact factor: 2.547

3.  Narcotic blockade.

Authors:  V P Dole; M E Nyswander; M J Kreek
Journal:  Arch Intern Med       Date:  1966-10

4.  Proceedings: The effect of delta-1-tetrahydrocannabinol on the noradrenaline and dopamine content of the brain and heart of the rat.

Authors:  J D Graham; M J Lewis; J Williams
Journal:  Br J Pharmacol       Date:  1974-11       Impact factor: 8.739

5.  Biochemical correlates in mouse-killing behavior of the rat: brain acetylcholine and acetylcholinesterase after administration of delta9-tetrahydrocannabinol.

Authors:  H Yoshimura; M Fujiwara; S Ueki
Journal:  Brain Res       Date:  1974-12-13       Impact factor: 3.252

6.  The role of dopamine and norepinephrine in the naloxone-induced abstinence of morphine-dependent mice.

Authors:  Y Maruyama; A E Takemori
Journal:  J Pharmacol Exp Ther       Date:  1973-06       Impact factor: 4.030

7.  Effect of chemical sympathectomy on morphine antinociception and tolerance development in the rat.

Authors:  H N Bhargava; A H Afifi; E L Way
Journal:  Biochem Pharmacol       Date:  1973-11-01       Impact factor: 5.858

8.  Elevation of brain dopamine during naloxone-precipitated withdrawal in morphine-dependent mice and rats.

Authors:  E T Iwamoto; I K Ho; E L Way
Journal:  J Pharmacol Exp Ther       Date:  1973-12       Impact factor: 4.030

9.  Possible anticholinesterase-like effects of trans(-) 8 and - 9 tetrahydrocannabinol as observed in the general motor activity of mice.

Authors:  H Brown
Journal:  Psychopharmacologia       Date:  1972

10.  Some anticholinergic-like behavioural effects of trans (-)- 8 tetrahydrocannabinol.

Authors:  H Brown
Journal:  Psychopharmacologia       Date:  1971
View more
  18 in total

1.  The impact of naturalistic cannabis use on self-reported opioid withdrawal.

Authors:  Cecilia L Bergeria; Andrew S Huhn; Kelly E Dunn
Journal:  J Subst Abuse Treat       Date:  2020-03-30

2.  Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal.

Authors:  Francisco Navarrete; Auxiliadora Aracil-Fernández; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2018-05-03       Impact factor: 8.739

3.  The effects of divalent ions on morphine analgesia and abstinence syndrome in morphine-tolerant and -dependent mice.

Authors:  H N Bhargava
Journal:  Psychopharmacology (Berl)       Date:  1978-04-28       Impact factor: 4.530

4.  A comparison of some pharmacological actions of morphine and delta9-tetrahydrocannabinol in the mouse.

Authors:  A S Bloom; W L Dewey
Journal:  Psychopharmacology (Berl)       Date:  1978-05-31       Impact factor: 4.530

5.  Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans.

Authors:  Michelle R Lofwall; Shanna Babalonis; Paul A Nuzzo; Samy Claude Elayi; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2016-05-10       Impact factor: 4.492

6.  Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice.

Authors:  Divya Ramesh; Gracious R Ross; Joel E Schlosburg; Robert A Owens; Rehab A Abdullah; Steven G Kinsey; Jonathan Z Long; Daniel K Nomura; Laura J Sim-Selley; Benjamin F Cravatt; Hamid I Akbarali; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2011-06-30       Impact factor: 4.030

Review 7.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

8.  Attenuation of morphine antinociceptive tolerance by a CB(1) receptor agonist and an NMDA receptor antagonist: Interactive effects.

Authors:  Bradford D Fischer; Sara J Ward; Fredrick E Henry; Linda A Dykstra
Journal:  Neuropharmacology       Date:  2009-08-21       Impact factor: 5.250

Review 9.  Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?

Authors:  Natalie E Zlebnik; Joseph F Cheer
Journal:  Annu Rev Neurosci       Date:  2016-02-24       Impact factor: 12.449

Review 10.  Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage.

Authors:  Yasmin L Hurd; Michelle Yoon; Alex F Manini; Stephanie Hernandez; Ruben Olmedo; Maria Ostman; Didier Jutras-Aswad
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.